Medical imaging is among the most important innovations of our times, but modern healthcare asks more from it than ever before.
Misclassification rates resulting in over- and under-diagnosis are too high in cardiology and oncology, driving costs. This uncertainty makes it even harder to measure change reliably, one of the requirements for the use of imaging in personalized medicine. Successive rounds of hardware innovations produce ever bigger data sets, ever richer – but which challenge unaided interpretation.
What would it look like to better align medical imaging to the goals of outcome-based reimbursement models needed by Accountable Care Organizations? To scale well to address the needs of integrated delivery networks?
Elucid Bioimaging addresses these needs using its patented, multi-modality, Computer-Aided Phenotyping (CAP) Platform, first in cardiology and oncology, with potential beyond.
- National Institutes of Health awards Elucid Bioimaging SBIR grant to establish vascuCAP as fit for use in both personalized medicine as well as drug development., August 2015
- Elucid Bioimaging featured in National Institutes of Health and the National Science Foundation Innovation Zone at 2015 BIO International Convention in Philadelphia, June 2015
- Publication: Role of the Quantitative Imaging Biomarker Alliance in Optimizing CT for the Evaluation of Lung Cancer Screen-Detected Nodules, Journal of the American College of Radiology, April 2015
- Elucid Bioimaging sponsors pilot study for the analysis of challenging lung nodules at Brigham & Women’s Hospital, Boston, MA, February 2015
- Publication: Determining the Variability of Lesion Size Measurements from CT Patient Datasets Acquired Under “No Change” Conditions, Translational Oncology, February 2015
- Q-CAMP, Quantitative Cardiovascular Magnetic Resonance Imaging and Profiling of Atherosclerotic Lesions, Study Continues in New Orleans and 2nd Clinical Site Opens in West Jefferson, November 2014
- Read More News...